EGFR and non-small cell lung carcinoma: Our study aimed to determine the efficacy and safety of aumolertinib as a first-line therapy in NSCLC patients aged ≥65 and <65 years in clinical practice.We enrolled 100 patients with stage IIA–IVB epidermal growth factor receptor-mutant NSCLC who received aumolertinib alone as the first-line therapy.